Marinus Pharmaceuticals, Inc. (MRNS) experienced a significant stock decline following the release of disappointing data from its Phase 3 TrustTSC trial for oral ganaxolone in treating seizures associated with tuberous sclerosis complex (TSC). The trial failed to meet its primary endpoint, leading the company to discontinue further ganaxolone development and explore strategic alternatives.
Nisichawayasihk Cree Nation in Manitoba is urging residents to be cautious after several community members experienced seizures and required medical attention following drug use. The specific drug or substance causing these reactions is still unknown, but the First Nation warns that it could be contaminated with potentially lethal substances like fentanyl. Police are investigating the matter.
